NASDAQ:BLRX - BIOLINERX LTD/S Stock Price, Forecast & News

BIOLINERX LTD/S trades on the NASDAQ under the ticker symbol "BLRX."

BIOLINERX LTD/S (NASDAQ:BLRX) released its quarterly earnings data on Thursday, August, 11th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.07). View BIOLINERX LTD/S's Earnings History.

BIOLINERX LTD/S is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for BIOLINERX LTD/S.

3 analysts have issued twelve-month price objectives for BIOLINERX LTD/S's stock. Their forecasts range from $3.00 to $10.00. On average, they expect BIOLINERX LTD/S's share price to reach $6.50 in the next year. This suggests a possible upside of 205.2% from the stock's current price. View Analyst Price Targets for BIOLINERX LTD/S.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLINERX LTD/S in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIOLINERX LTD/S.

News coverage about BLRX stock has trended negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. BIOLINERX LTD/S earned a news sentiment score of -2.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for BIOLINERX LTD/S.

Some companies that are related to BIOLINERX LTD/S include DiaMedica Therapeutics (DMAC), Alpine Immune Sciences (ALPN), Acer Therapeutics (ACER), NewLink Genetics (NLNK), Aclaris Therapeutics (ACRS), American Brivision (Holding) (ABVC), Tiziana Life Sciences (TLSA), resTORbio (TORC), Processa Pharmaceuticals (PCSA), AgeX Therapeutics (AGE), Vascular Biogenics (VBLT), Acasti Pharma (ACST), Forward Pharma A/S (FWP), Bellicum Pharmaceuticals (BLCM) and PLx Pharma (PLXP).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLINERX LTD/S investors own include Savara (SVRA), Synergy Pharmaceuticals (SGYP), Brainstorm Cell Therapeutics (BCLI), Ballard Power Systems (BLDP), Protalix Biotherapeutics (PLX), Corbus Pharmaceuticals (CRBP), Eyepoint Pharmaceuticals (EYPT), Verastem (VSTM), Advaxis (ADXS) and Agile Therapeutics (AGRX).

BIOLINERX LTD/S's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Senvest Management LLC (8.41%) and Cutter & CO Brokerage Inc. (0.16%).

BLRX stock was bought by a variety of institutional investors in the last quarter, including Senvest Management LLC and Cutter & CO Brokerage Inc..

Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BLRX stock can currently be purchased for approximately $2.13.

BIOLINERX LTD/S has a market capitalization of $15.93 million. The biotechnology company earns $-22,960,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. BIOLINERX LTD/S employs 51 workers across the globe.View Additional Information About BIOLINERX LTD/S.

The official website for BIOLINERX LTD/S is http://www.biolinerx.com/.

BIOLINERX LTD/S's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-2548-9100 or via email at [email protected]